Vir Biotechnology Inc


Prices are adjusted according to historical splits.

Vir Biotechnology Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$1.68 billion
Book Value:
Revenue TTM:
$490.72 million
Operating Margin TTM:
Gross Profit TTM:
$1.03 billion
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Vir Biotechnology Inc had its IPO on 2019-10-11 under the ticker symbol VIR.

The company operates in the Healthcare sector and Biotechnology industry. Vir Biotechnology Inc has a staff strength of 576 employees.

Stock update

Shares of Vir Biotechnology Inc opened at $10.68 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $10.47 - $10.82, and closed at $10.49.

This is a -2.24% slip from the previous day's closing price.

A total volume of 1,689,807 shares were traded at the close of the day’s session.

In the last one week, shares of Vir Biotechnology Inc have slipped by -16.15%.

Vir Biotechnology Inc's Key Ratios

Vir Biotechnology Inc has a market cap of $1.68 billion, indicating a price to book ratio of 1.6037 and a price to sales ratio of 1.4094.

In the last 12-months Vir Biotechnology Inc’s revenue was $490.72 million with a gross profit of $1.03 billion and an EBITDA of $-255975008. The EBITDA ratio measures Vir Biotechnology Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Vir Biotechnology Inc’s operating margin was -55.02% while its return on assets stood at -6.94% with a return of equity of -13.93%.

In Q2, Vir Biotechnology Inc’s quarterly earnings growth was a positive 58.5% while revenue growth was a negative 94.9%.

Vir Biotechnology Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.9 per share while it has a forward price to earnings multiple of 4.3611 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vir Biotechnology Inc’s profitability.

Vir Biotechnology Inc stock is trading at a EV to sales ratio of 0.5203 and a EV to EBITDA ratio of 0.7891. Its price to sales ratio in the trailing 12-months stood at 1.4094.

Vir Biotechnology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$2.24 billion
Total Liabilities
$225.62 million
Operating Cash Flow
$230.32 million
Capital Expenditure
$9.46 million
Dividend Payout Ratio

Vir Biotechnology Inc ended 2023 with $2.24 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.24 billion while shareholder equity stood at $1.81 billion.

Vir Biotechnology Inc ended 2023 with $0 in deferred long-term liabilities, $225.62 million in other current liabilities, 13000.00 in common stock, $41.56 million in retained earnings and $16.94 million in goodwill. Its cash balance stood at $666.95 million and cash and short-term investments were $1.85 billion. The company’s total short-term debt was $13,536,000 while long-term debt stood at $0.

Vir Biotechnology Inc’s total current assets stands at $1.95 billion while long-term investments were $52.36 million and short-term investments were $1.18 billion. Its net receivables were $16.85 million compared to accounts payable of $12.36 million and inventory worth $0.

In 2023, Vir Biotechnology Inc's operating cash flow was $230.32 million while its capital expenditure stood at $9.46 million.

Comparatively, Vir Biotechnology Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Vir Biotechnology Inc stock is currently trading at $10.49 per share. It touched a 52-week high of $31.55 and a 52-week low of $31.55. Analysts tracking the stock have a 12-month average target price of $33.88.

Its 50-day moving average was $15.5 and 200-day moving average was $22.98 The short ratio stood at 2.65 indicating a short percent outstanding of 0%.

Around 1425.7% of the company’s stock are held by insiders while 7595.1% are held by institutions.

Frequently Asked Questions About Vir Biotechnology Inc

The stock symbol (also called stock or share ticker) of Vir Biotechnology Inc is VIR

The IPO of Vir Biotechnology Inc took place on 2019-10-11

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.


499 Illinois Street, San Francisco, CA, United States, 94158